| Clinical features and outcomes of immune checkpoint inhibitor–associated AKI: a multicenter study FB Cortazar, ZA Kibbelaar, IG Glezerman, A Abudayyeh, O Mamlouk, ... Journal of the American Society of Nephrology 31 (2), 435-446, 2020 | 342 | 2020 |
| Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature N Abdel-Wahab, H Safa, A Abudayyeh, DH Johnson, VA Trinh, ... Journal for immunotherapy of cancer 7, 1-10, 2019 | 291 | 2019 |
| Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience O Mamlouk, U Selamet, S Machado, M Abdelrahim, WF Glass, ... Journal for immunotherapy of cancer 7, 1-13, 2019 | 269 | 2019 |
| Nuclear receptor 4A (NR4A) family–orphans no more S Safe, UH Jin, B Morpurgo, A Abudayyeh, M Singh, RB Tjalkens The Journal of steroid biochemistry and molecular biology 157, 48-60, 2016 | 201 | 2016 |
| Acute kidney injury in patients treated with immune checkpoint inhibitors S Gupta, SAP Short, ME Sise, JM Prosek, SM Madhavan, MJ Soler, ... Journal for immunotherapy of cancer 9 (10), e003467, 2021 | 171 | 2021 |
| A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant N Murakami, P Mulvaney, M Danesh, A Abudayyeh, A Diab, ... Kidney international 100 (1), 196-205, 2021 | 158 | 2021 |
| Oncogenic microRNA‐27a is a target for anticancer agent methyl 2‐cyano‐3, 11‐dioxo‐18β‐olean‐1, 12‐dien‐30‐oate in colon cancer cells S Chintharlapalli, S Papineni, M Abdelrahim, A Abudayyeh, I Jutooru, ... International journal of cancer 125 (8), 1965-1974, 2009 | 153 | 2009 |
| Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors V Nair, S Sreevalsan, R Basha, M Abdelrahim, A Abudayyeh, AR Hoffman, ... Journal of Biological Chemistry 289 (40), 27692-27701, 2014 | 145 | 2014 |
| Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met S Papineni, S Chintharlapalli, M Abdelrahim, S Lee, R Burghardt, ... Carcinogenesis 30 (7), 1193-1201, 2009 | 104 | 2009 |
| Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression S Konduri, J Colon, CH Baker, S Safe, JL Abbruzzese, A Abudayyeh, ... Molecular cancer therapeutics 8 (3), 533-542, 2009 | 84 | 2009 |
| Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice J Colon, MR Basha, R Madero-Visbal, S Konduri, CH Baker, LJ Herrera, ... Investigational new drugs 29, 41-51, 2011 | 80 | 2011 |
| Paraprotein–related kidney disease: evaluation and treatment of myeloma cast nephropathy KW Finkel, EP Cohen, A Shirali, A Abudayyeh Clinical Journal of the American Society of Nephrology 11 (12), 2273-2279, 2016 | 72 | 2016 |
| Renal toxicities of novel agents used for treatment of multiple myeloma R Wanchoo, A Abudayyeh, M Doshi, A Edeani, IG Glezerman, D Monga, ... Clinical Journal of the American Society of Nephrology 12 (1), 176-189, 2017 | 71 | 2017 |
| Nuclear receptor 4A1 (NR4A1) as a drug target for renal cell adenocarcinoma E Hedrick, SO Lee, G Kim, M Abdelrahim, UH Jin, S Safe, A Abudayyeh PloS one 10 (6), e0128308, 2015 | 71 | 2015 |
| RNAi and cancer: Implications and applications M Abdelrahim, S Safe, C Baker, A Abudayyeh Journal of RNAi and gene silencing: an international journal of RNA and gene …, 2006 | 60 | 2006 |
| Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis JS Lin, O Mamlouk, U Selamet, A Tchakarov, WF Glass, RA Sheth, ... Oncoimmunology 10 (1), 1877415, 2021 | 52 | 2021 |
| Transplant oncology: an evolving field in cancer care M Abdelrahim, A Esmail, A Abudayyeh, N Murakami, A Saharia, ... Cancers 13 (19), 4911, 2021 | 51 | 2021 |
| Symptomatic BK virus infection is associated with kidney function decline and poor overall survival in allogeneic hematopoietic stem cell recipients A Abudayyeh, A Hamdi, H Lin, M Abdelrahim, G Rondon, BS Andersson, ... American Journal of Transplantation 16 (5), 1492-1502, 2016 | 51 | 2016 |
| Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events F Fa'ak, M Buni, A Falohun, H Lu, J Song, DH Johnson, CM Zobniw, ... Journal for immunotherapy of cancer 11 (6), e006814, 2023 | 49 | 2023 |
| Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: a case report M Abdelrahim, A Esmail, G Umoru, K Westhart, A Abudayyeh, A Saharia, ... Current Oncology 29 (6), 4267-4273, 2022 | 48 | 2022 |
